Cargando…

A review of avelumab in locally advanced and metastatic bladder cancer

Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Arpit, Patel, Manish R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354303/ https://www.ncbi.nlm.nih.gov/pubmed/30728859 http://dx.doi.org/10.1177/1756287218823485

Ejemplares similares

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
por: Averbuch, Itamar, et al.
Publicado: (2023)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses
por: Wood, Laura S., et al.
Publicado: (2022)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

Treatment of locally advanced and metastatic bladder cancer
por: Khochikar, Makarand V.
Publicado: (2008)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

Re-Induction of Avelumab for Patients with Metastatic Merkel Cell Carcinoma
por: Hiroyuki, Goto, et al.
Publicado: (2023)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
por: Pyrgidis, Nikolaos, et al.
Publicado: (2023)

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
por: Dirix, Luc Y., et al.
Publicado: (2017)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes
por: Ten Eyck, Jennifer E, et al.
Publicado: (2022)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
por: Keilholz, Ulrich, et al.
Publicado: (2019)

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma
por: Novakovic, Ana M., et al.
Publicado: (2019)

A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
por: Chang, Wen‐Cheng, et al.
Publicado: (2021)

Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
por: Dobrzynski, Jeffrey L., et al.
Publicado: (2022)

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer
por: Kokura, Kazuki, et al.
Publicado: (2023)

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
por: Bharmal, Murtuza, et al.
Publicado: (2019)

Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
por: Tun Min, Sandy, et al.
Publicado: (2019)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
por: Tintelnot, Joseph, et al.
Publicado: (2022)

Efficacy and immune-related adverse event associations in avelumab-treated patients
por: Kelly, Karen, et al.
Publicado: (2020)

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival
por: Lohray, Rishabh, et al.
Publicado: (2023)

Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
por: Lonardi, Sara, et al.
Publicado: (2021)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review
por: Sagaram, Smitha, et al.
Publicado: (2021)

Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review
por: van Hattum, Jons W., et al.
Publicado: (2021)

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
por: Koshkin, Vadim S., et al.
Publicado: (2019)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
por: Coquan, Elodie, et al.
Publicado: (2022)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
por: Apolo, Andrea B., et al.
Publicado: (2017)

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
por: Apolo, Andrea B, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u7lh9qenprmdg678fspbm9plrp